Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from LungLife AI ( (GB:LLAI) ) is now available.
LungLife AI announced the successful passing of resolutions at a Special Meeting, leading to the cancellation of its Common Shares trading on AIM, effective 29 May 2025. Additionally, the company is advancing towards completing an Exclusive License and Distribution Agreement with Circulogene Theranostics, anticipated in Q2 2025, which may enhance its market positioning and operational capabilities.
More about LungLife AI
LungLife AI is a company specializing in clinical diagnostic solutions aimed at the early detection of lung cancer, the deadliest form of cancer worldwide. Their primary product, the LungLB® test, utilizes a minimally invasive blood draw to provide additional information to clinicians assessing indeterminate lung nodules.
Average Trading Volume: 536,271
Technical Sentiment Signal: Sell
For a thorough assessment of LLAI stock, go to TipRanks’ Stock Analysis page.